title: Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
abstract: BACKGROUND
  Long-term treatment with lamivudine is required to control viral replication in patients with hepatitis B e antigen-negative chronic hepatitis B, but is associated with a high rate of viral resistance. The role of adefovir dipivoxil in these patients has not been definitively evaluated.
  
  
  OBJECTIVE
  To address the role of adefovir in the management of patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
  
  
  METHODS
  Patients were assigned to receive adefovir 10 mg once daily plus ongoing lamivudine 100 mg once daily for 52 weeks. The primary end point was reduction in serum hepatitis B virus DNA level (hepatitis B virus DNA response). Secondary end points included the proportion of patients with undetectable hepatitis B virus DNA at week 52 (complete virological response) and the percentage of patients with normalization of alanine transferase level at week 52 (biochemical response).
  
  
  RESULTS
  A total of 49 consecutive patients were enrolled in this study. After 52 weeks of treatment, all patients had an hepatitis B virus DNA response and 57.1% had complete virological response. Biochemical response occurred in 75.6% of patients.
  
  
  CONCLUSIONS
  Administration of adefovir in patients with lamivudine-resistant chronic hepatitis B results in significant suppression of viral replication. Nevertheless, continuous therapy will probably be needed in order to maintain remission in these patients.
authors.affiliation: 2nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Vassiliadis
authors.forename: N
authors.initials: N
authors.lastname: Nikolaidis
authors.forename: O
authors.initials: O
authors.lastname: Giouleme
authors.forename: K
authors.initials: K
authors.lastname: Tziomalos
authors.forename: N
authors.initials: N
authors.lastname: Grammatikos
authors.forename: K
authors.initials: K
authors.lastname: Patsiaoura
authors.forename: P
authors.initials: P
authors.lastname: Zezos
authors.forename: D
authors.initials: D
authors.lastname: Gkisakis
authors.forename: K
authors.initials: K
authors.lastname: Theodoropoulos
authors.forename: P
authors.initials: P
authors.lastname: Katsinelos
authors.forename: E
authors.initials: E
authors.lastname: Orfanou-Koumerkeridou
authors.forename: N
authors.initials: N
authors.lastname: Eugenidis
mesh_terms: D000225:Adenine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D024882:Drug Resistance, Viral; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D004338:Drug Combinations; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D019259:Lamivudine; D000225:Adenine; C106812:adefovir dipivoxil